Please select the eligibility criteria that correspond to the clinical trial below.
Title: Atorvastatin Compared With Simvastatin In The Prevention of CHD Morbidity And Mortality In Patients With CHD
Brief Summary: To investigate whether a long-term strategy to lower LDL cholesterol with atorvastatin as much as possible will improve prognosis in CHD patients compared with a strategy reflecting current best clinical practice with simvastatin.


Options:
A: Inclusion Criteria:

* Previous myocardial infarction

Exclusion Criteria:

* Women who are breast feeding or are pregnant
B: Inclusion Criteria:

* Diabetes mellitus type 1 or type 2
* With or without established microalbuminuria (albumin-to-creatinine ratio (ACR)2,5-25 mg/mmol for men, and 3,5-25 mg/mmol for women, according to ISH and ESC recommended criteria)
* Glomerular filtration rate (GFR) between 15-60 ml/min/1.73m2 (measured the last 6 months) or GFR \>75ml/min/1.73m2. The abbreviated Modification of Diet in Renal Disease (MDRD) equation will be used to calculate GFR.
* Age 18-80 years

Exclusion Criteria:

* Definite history of myocardial infarction, coronary revascularisation procedure or stroke. (i.e, a strong clinical indication for statin treatment)
* Functioning renal transplant, or living donor-related transplant planned.
* Patients on dialysis.
* Poor metabolic control, i.e HbA1c \> 9%
* Definite history of chronic liver disease, or abnormal liver function (i.e ALT \>1,5 x ULN or, if ALT not available, AST \> 1,5 x ULN).
* Evidence of active inflammatory muscle disease (e.g dermatomyositis, polymyositis), or CK\>3 x ULN;
* Definite previous adverse reaction to a statin or to ezetimibe
* Definite previous adverse reaction to acetylsalicylic acid.
* Definite previous adverse reaction to an ACE-inhibitor.
* Need for concomitant treatment with a strong inhibitor of CYP3A4, such as itrokonazole, ketokonazole, erythromycin, clarithromycin, HIV-protease inhibitors or nefazodone (i.e. agents that may markedly elevate simvastatin levels).
C: Inclusion Criteria:

* Individuals between 18 and 85 years of age
* Individuals with any psychiatric disorder who are taking lithium

  o Patients will be recruited from the Douglas Mental Health University Institute, Jewish General Hospital and McGill University Health Centre.
* Able and willing to give informed consent.
* Chronic and current lithium users (at least 2 months of Lithium use).
* Stable dose of lithium for the past 2 months.
* Patients taking any lithium level will be included.
* Patients with any psychiatric diagnosis will also be included.
* NDI defined as a 10-hour water restriction UOsm \<600mOsm/Kg.

Exclusion Criteria:

* Patients allergic to Statins
* Patients with statin use within 6 weeks prior to the study
* Patients with a past history of severe adverse reaction to statins.
* Patients with a baseline Low Density Lipoprotein (LDL) level \<1.5.
* Relative contraindications to statin use 42: pregnancy or lactation, concurrent use of fibrates, heavy ethanol consumption (\>50 units/week).
* Incapacity to consent
* Deemed by the treating physician to have a severe cognitive or behavioural disturbance such as acute delirium or moderate-severe DSM5 Neurocognitive Disorder (dementia), preventing their ability to complete safely the study questionnaire and/or to provide blood and urine test.
D: Inclusion Criteria:

* Type 2 diabetes
* Persistent microalbuminuria
* Fasting plasma cholesterol \> 5.5 mmol/liter
* Fasting plasma triglycerides \< 4.5 mmol/liter
* Fasting HbA1c \< 10 %
* Fasting serum C-peptide \> 0.49 nmol/liter
* Blood pressure \< 155/95

Exclusion Criteria:

* Signs of primary kidney disease
* Signs of primary hepatic disease
* Signs of insufficiently treated cardiac disease

Answer: A